Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H10O5S |
Molecular Weight | 254.259 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(CC(=O)C2=CC=CC=C2C1=O)S(O)(=O)=O
InChI
InChIKey=WIXFIQKTHUVFDI-UHFFFAOYSA-N
InChI=1S/C11H10O5S/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13/h2-5H,6H2,1H3,(H,14,15,16)
Molecular Formula | C11H10O5S |
Molecular Weight | 254.259 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14952541Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/3927923 | https://www.ncbi.nlm.nih.gov/pubmed/18935165 | https://www.ncbi.nlm.nih.gov/pubmed/26212258
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14952541
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/3927923 | https://www.ncbi.nlm.nih.gov/pubmed/18935165 | https://www.ncbi.nlm.nih.gov/pubmed/26212258
Menadione bisulfite is a water-soluble analog of Vitamin K3. Pharmacologic studies on menadione bisulfate indicad that its toxicity is relatively low. In man, doses approximately ten times as great as those generally recommended for therapeutic use, given daily for a period of one week. Redox cycling compounds, such as menadione, have the potential to effectively mitigate the toxicity of organophosphorus pesticides including parathion. Menadione bisulfite behaved as a competitive inhibitor of chicken muscle aldose reductase.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11081416 |
|||
Target ID: CHEMBL2169730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9324955 |
|||
Target ID: Aldose reductase (Gallus gallus) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3927923 |
0.025 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 10 times / day multiple, oral Highest studied dose Dose: 10 mg, 10 times / day Route: oral Route: multiple Dose: 10 mg, 10 times / day Co-administed with:: Vitamin C, p.o(500 mg; 10 times/day) Sources: Page: p.64 |
unhealthy, 56 – 85 n = 3 Health Status: unhealthy Condition: Prostate cancer Age Group: 56 – 85 Sex: M Population Size: 3 Sources: Page: p.64 |
PubMed
Title | Date | PubMed |
---|---|---|
[A computer method for assessing the average rate of movement of Paramecium caudatum by a cross-sectional light beam]. | 2002 Jan-Feb |
|
Detection of reactive free radicals derived from nucleosides by liquid chromatography coupled to tandem mass spectrometry of DMPO spin trapping adducts. | 2006 |
|
NDX-1 protein hydrolyzes 8-oxo-7, 8-dihydrodeoxyguanosine-5'-diphosphate to sanitize oxidized nucleotides and prevent oxidative stress in Caenorhabditis elegans. | 2011 Dec |
|
Structures of the PutA peripheral membrane flavoenzyme reveal a dynamic substrate-channeling tunnel and the quinone-binding site. | 2014 Mar 4 |
|
Vitamin K3 (menadione) redox cycling inhibits cytochrome P450-mediated metabolism and inhibits parathion intoxication. | 2015 Oct 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14952541
5 mg. Therapy, averaging thirty days, was continued until the withdrawal of metlication produced no recurrence of symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2250668
Addition of menadione bisulfite (3 mM) alone to the perfusate increased oxygen uptake by 20-30 uM/g/hr. In the presence of ethanol, maximal increases in oxygen uptake due to menadione bisulfite were much larger (about 90 uM/g/hr), and lactate dehydrogenase release occurred earlier and reached higher maximal values (330 units/g/hr).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:55:57 GMT 2023
by
admin
on
Fri Dec 15 15:55:57 GMT 2023
|
Record UNII |
I2BE1ZEN8I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
I2BE1ZEN8I
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
63930
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
8536
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
300000029211
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
130-36-9
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |